TOP TEN perturbations for P35590 (Homo sapiens)

Organism: Homo sapiens
Gene: P35590
Selected probe(set): 204468_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P35590 (204468_s_at) across 5339 perturbations tested by GENEVESTIGATOR:

stem cell differentiation study 41 (hES-T3 EB) / undifferentiated hES-T3 cell sample

Relative Expression (log2-ratio):4.3161554
Number of Samples:2 / 3
Experimental stem cell differentiation study 41 (hES-T3 EB)
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype.
Control undifferentiated hES-T3 cell sample
Undifferentiated human embryonic stem cells T3.

stem cell differentiation study 41 (T3pi) / stem cell differentiation study 41 (hES-T3 EB)

Relative Expression (log2-ratio):-4.280155
Number of Samples:2 / 2
Experimental stem cell differentiation study 41 (T3pi)
Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control stem cell differentiation study 41 (hES-T3 EB)
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype.

PMA study 8 (0.0001 uM; Hep-G2) / vehicle (DMSO) treated Hep-G2 cell sample

Relative Expression (log2-ratio):4.2248373
Number of Samples:3 / 9
Experimental PMA study 8 (0.0001 uM; Hep-G2)
Hep-G2 cells exposed to 0.0001 uM PMA (dissolved in 0.5% v/v DMSO) for 72 hours. Synonyms: phorbol-12-myristat-13-acetate (PMA), tetradecanoylphorbol-acetate (TPA), tetradecanoyl phorbol acetate, 12-O-tetradecanoylphorbol-13-acetate. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (DMSO) treated Hep-G2 cell sample
Hep-G2 cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached.

renal cell carcinoma study 5 (papillary type) / normal kidney tissue

Relative Expression (log2-ratio):-3.510271
Number of Samples:19 / 2
Experimental renal cell carcinoma study 5 (papillary type)
Tumor tissue samples from the kidney of patients with papillary renal cell carcinoma (pRCC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

monocyte activation study 1 (NOD2L; 24h) / monocyte activation study 1 (NOD2L; 6h)

Relative Expression (log2-ratio):3.173603
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells.
Control monocyte activation study 1 (NOD2L; 6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells.

collecting duct carcinoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):-3.141347
Number of Samples:2 / 2
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

PMA study 7 (24h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):3.0418239
Number of Samples:3 / 7
Experimental PMA study 7 (24h)
HepG2 cells exposed to 500nM phorbol-12-myristat-13-acetate [(PMA ortetradecanoyl phorbol acetate (TPA)] in DMSO solvent for 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 24 hours.

breast cancer study 8 (primary) / normal breast tissue

Relative Expression (log2-ratio):-3.0150995
Number of Samples:13 / 4
Experimental breast cancer study 8 (primary)
Human primary infiltrating ductal carcinoma sample of a female patient with breast cancer.
Control normal breast tissue
Normal human breast samples of healthy female individuals.

renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue

Relative Expression (log2-ratio):-2.9941607
Number of Samples:4 / 2
Experimental renal cell carcinoma study 6 (chromophobe type)
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

monocyte activation study 1 (TLR/1L; 24h) / monocyte activation study 1 (NOD2L; 24h)

Relative Expression (log2-ratio):-2.9604635
Number of Samples:5 / 5
Experimental monocyte activation study 1 (TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control monocyte activation study 1 (NOD2L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells.